CN110731340A

CN110731340A - medicinal synergist for preventing and treating armyworm and its application method

Info

Publication number: CN110731340A
Application number: CN201911035543.6A
Authority: CN
Inventors: 杜孟芳; 安世恒; 刘少凯; 刘晓光; 魏纪珍
Original assignee: Henan Agricultural University
Current assignee: Henan Agricultural University
Priority date: 2019-10-29
Filing date: 2019-10-29
Publication date: 2020-01-31
Anticipated expiration: 2039-10-29
Also published as: CN110731340B

Abstract

The invention belongs to the field of toxicological activity of pest control, and particularly relates to pesticide synergists for preventing and controlling armyworms and a use method thereof. pesticide synergists for preventing and controlling the armyworms, wherein the synergist is cyclosporine A, the pesticide is spinosad, and the armyworms are 2-instar larvae.

Description

medicinal synergist for preventing and treating armyworm and its application method

Technical Field

The invention belongs to the field of toxicological activity of pest control, and particularly relates to pesticide synergists for controlling armyworms and a using method thereof.

Background

Mythimna (A)Mythimna separata(Walker) It belongs to lepidoptera noctuidae, also called as cutworm, marching insect, commonly called as confetti insect and wheat silkworm, and is kinds of omnivorous, migratory and intermittent explosive pests which mainly use grain crops such as wheat, corn, sorghum, rice and the like and pasture grass, and can harm more than 16 kinds of more than 104 kinds of plants in 16 families, especially the favorite gramineous plants, except for northwest local areas, the mythimna insect can eat leaves of the crops in an exposure way, and seriously damages the growth of the crops.

At present, chemical control is mainly adopted for preventing and treating the armyworm, spinosad is compounds of macrolide compounds which have very novel and unique structures and are different from , the unique chemical structure determines the unique insecticidal mechanism of the compound, the spinosad has quick contact poisoning and ingestion toxicity to insects, has the characteristic poisoning symptom of nerve toxicants, has the characteristics of low toxicity, low residue, safety to natural enemies of insects and quick natural decomposition by stimulating the nervous system of the insects to increase the spontaneous activity of the insects, causing non-functional muscle contraction and failure and accompanying trembling and paralysis death, and is an antibiotic insecticide produced by fermentation of actinomycete saccharopolyspora spinosa, so the control effect of the spinosad on the armyworm needs to be improved by steps in production practice.

At present, the spinosad synergist for preventing and controlling armyworm is compounded by adopting a plurality of pesticides, for example, the spinosad synergist is mixed with chlorpyrifos, because the nerve toxicants cannot eliminate the potential risks of the same or similar action mechanism, cross resistance is easy to generate, the residual pollution to the environment and crops cannot be avoided, and no green synergist for enhancing the activity of the spinosad is found and applied at present.

Therefore, pleocidin synergists are urgently needed, and the effect of pleocidin on treating armyworms can be improved.

Disclosure of Invention

Aiming at the problem that a spinosad synergist for preventing and controlling myxoma is absent at present, the spinosad and cyclosporine A are mixed and proportioned for use, the synergy condition of the spinosad is evaluated by comparing the predicted mortality with the actual mortality, and the synergist amount of the cyclosporine A is determined.

The technical scheme of the invention is realized as follows:

kinds of pesticide synergist for preventing and killing armyworm, and the synergist is cyclosporin A.

The drug is spinosad.

The myxozoa are 2-instar larvae.

A method for preventing and controlling armyworm by using a medicament synergist comprises the steps of mixing spinosad with a certain concentration and cyclosporine A, then mixing the mixture with artificial feed of the armyworm, and feeding the mixture.

The final concentration of the spinosad is 0.5 mg/L, and the final concentration of the cyclosporine A is 50-100 mu M.

The invention has the following beneficial effects:

1. the inventor of the application utilizes the anti-rejection reaction which is mainly used for human liver, kidney and heart transplantation clinically, and the effect of combining the drug cyclosporin A for treating immune diseases with the adrenocortical hormone to synergize the bactericidal effect of the spinosad.

2. Researches find that 50 mu M of cyclosporin A can remarkably enhance the effect of spinosad on preventing and controlling 2-instar larvae of myxozoa. Cyclosporine A and spinosad at 100 mu M can cause 100% of actual observed corrected mortality of myxozoa, the combination of 100 mu M of cyclosporine A and 0.5 mg/L of spinosad is predicted, the predicted corrected mortality is 89.74%, and the actual observed corrected mortality is obviously higher than the predicted corrected mortality (the ratio of the actual observed corrected mortality is lower than the ratio of the predicted corrected mortality: (the ratio of the actual observed corrected mortality is lower than the ratio of the predicted corrected mortality by the aid of the spinosad) (theP= 0.0002), indicating that 100 μ M cyclosporin a can significantly potentiate spinosad control myxomycete larvae at 2 th instar.

Drawings

In order to more clearly illustrate the embodiments of the present invention or the technical solutions in the prior art, the drawings used in the description of the embodiments or the prior art will be briefly described below, it is obvious that the drawings in the following description are only embodiments of the present invention, and other drawings can be obtained by those skilled in the art without creative efforts.

FIG. 1 is a graph of predicted mortality and observed mortality for myxomatous 2 instar larvae with spinosad in combination with cyclosporin A; the numbers in parentheses on the abscissa represent the concentrations of cyclosporin A at 50. mu.M and 100. mu.M, respectively.

Detailed Description

The technical solution of the present invention will be described clearly and completely with reference to the embodiments of the present invention, and it should be understood that the described embodiments are only a partial embodiment , rather than a complete embodiment.

Example pesticide synergist for preventing and controlling armyworm and its application method

1.1 test armyworm

Mythimna separata 2-instar larvae.

1.2 concentration ratio of Cyclosporin A and Spinosad

The concentration of spinosad was selected to be 0.5 mg/L, and mixed with different concentrations of cyclosporin A (50. mu.M and 100. mu.M).

1.3 bioassay method

The method comprises the steps of mixing medicaments with artificial feed (34 g of yeast powder, 40 g of wheat germ powder and 100 g of corn leaf powder, uniformly stirring, boiling and uniformly mixing 2 g of sorbic acid, 4 g of methylparaben and 300 mL of distilled water, adding the mixture into ①, uniformly stirring, boiling and uniformly mixing 3, 600 mL of distilled water and 18 g of agar powder, uniformly stirring, adding ② after the temperature is reduced to 40 ℃, uniformly stirring, adding 5-6 drops of VC 2.5g of linoleic acid (soybean oil), uniformly stirring, storing at 5 and 4 ℃, carrying out biological assay, namely preparing the mythimna separata artificial feed, mixing pleocidin or cyclosporine A into the mythimna artificial feed before the feed is cooled and solidified, cutting the feed into blocks, placing the feed into 100 mL of plastic cups for experiment, placing 12 heads of larvae into each small plastic cup, repeating for four times, and checking the death condition on the fourth day.

1.4 data analysis

All treatment mortality was corrected for controls to give corrected mortality as shown in the following table:

TABLE 1

With specific reference to the formula: corrected mortality (%) = (treatment mortality-control mortality)/(1-control mortality) × 100%. The predicted mortality rate upon combination was calculated according to the formula [1-S (spinosad) × S (cyclosporin a) ] × 100%, and then Student' S t variance analysis (DPS) was performed on the predicted mortality rate and the actually observed mortality rate, which was synergistic when the actually observed mortality rate was significantly higher than the predicted mortality rate (fig. 1).

1.5 synergistic condition and proportion.

Bioassay was performed on 2 nd armyworm larvae with 2 nd armyworm treated at 50 μ M and 100 μ M cyclosporin A concentrations, with average corrected mortality of 1.86% and 33.83%. 0.5 mg/L spinosad causes 50% of 2-year-old myxozoa to die, and the death rate is 79.50% after correcting the death rate; when 0.5 mg/L of spinosad is mixed with different concentrations of cyclosporin A (50 mu M and 100 mu M) respectively for use, the cyclosporin A and the spinosad can cause 100% of actual observed corrected mortality of myxozoa at 50 mu M, and the combination of 50 mu M of cyclosporin A and 0.5 mg/L of spinosad is predicted, and the predicted corrected mortality is 79.52%. The actual observed corrected mortality is significantly higher than the predicted corrected mortality (P= 0.0002)), as shown in figure 1, indicating that 50 μ M cyclosporin a can significantly potentiate spinosad control of myxomycete 2-instar larvae. The cyclosporin A and spinosad can cause 100% of actual observed corrected mortality of armyworm at 100 μ M, and the combination of the cyclosporin A at 100 μ M and the spinosad at 0.5 mg/L is predicted, and the corrected mortality should be predictedIt was 89.74%. The actual observed corrected mortality is significantly higher than the predicted corrected mortality (P= 0.0002), indicating that 100 μ M cyclosporin a can significantly potentiate spinosad control myxomycete larvae at 2 th instar. According to the principle of saving cost and reducing the use of medicaments, the cyclosporin A with the concentration of 50 mu M can remarkably enhance the effect of the spinosad on preventing and controlling the larvae of the armyworm with the age of 2.

The above description is only for the purpose of illustrating the preferred embodiments of the present invention and is not to be construed as limiting the invention, and any modifications, equivalents, improvements and the like that fall within the spirit and principle of the present invention are intended to be included therein.

Claims

1, kinds of medicinal synergist for preventing and treating armyworm, which is characterized in that the synergist is cyclosporine A.

2. The insecticide synergist for preventing and treating mythimna as claimed in claim 1, wherein: the drug is spinosad.

3. The insecticide synergist for preventing and treating mythimna as claimed in claim 1, wherein: the myxozoa are 2-instar larvae.

4. A method for controlling mythimna separata with the medicinal synergist in any claim 1-3, wherein the method comprises mixing concentration of spinosad with cyclosporin A, mixing with artificial feed for mythimna separata, and feeding.

5. The method for controlling armyworm using a pharmaceutical synergist according to claim 4, wherein: the final concentration of the spinosad is 0.5 mg/L, and the final concentration of the cyclosporine A is 50-100 mu M.